Medifast, Inc.
MED
$13.40
$0.211.59%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -37.38% | -33.77% | -37.70% | -40.58% | -43.09% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -37.38% | -33.77% | -37.70% | -40.58% | -43.09% |
| Cost of Revenue | -35.92% | -33.65% | -37.99% | -41.04% | -47.21% |
| Gross Profit | -37.91% | -33.82% | -37.60% | -40.42% | -41.42% |
| SG&A Expenses | -41.17% | -28.60% | -34.44% | -31.95% | -23.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -39.57% | -29.86% | -35.12% | -34.37% | -31.48% |
| Operating Income | 86.47% | -115.89% | -91.83% | -91.74% | -120.35% |
| Income Before Tax | 127.00% | -95.46% | -86.99% | -94.06% | -127.23% |
| Income Tax Expenses | 115.83% | -60.29% | -87.42% | -86.86% | -128.24% |
| Earnings from Continuing Operations | 130.41% | -109.28% | -86.73% | -95.12% | -126.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 130.41% | -109.28% | -86.73% | -95.12% | -126.93% |
| EBIT | 86.47% | -115.89% | -91.83% | -91.74% | -120.35% |
| EBITDA | 161.95% | -81.98% | 8.77% | -92.34% | -111.43% |
| EPS Basic | 130.26% | -109.25% | -86.79% | -95.14% | -126.81% |
| Normalized Basic EPS | 126.86% | -95.48% | -87.04% | -94.08% | -127.10% |
| EPS Diluted | 129.33% | -109.28% | -87.20% | -95.28% | -127.08% |
| Normalized Diluted EPS | 126.70% | -95.46% | -87.04% | -94.08% | -127.18% |
| Average Basic Shares Outstanding | 0.49% | 0.36% | 0.41% | 0.41% | 0.45% |
| Average Diluted Shares Outstanding | 1.12% | -0.09% | 0.44% | 0.35% | 0.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 1.82% | -3.94% | -1.00% | -1.00% | -1.00% |